Modality
Bispecific Ab
MOA
CGRPant
Target
TNFα
Pathway
Apoptosis
MG
Development Pipeline
Preclinical
~Jun 2021
→ ~Sep 2022
Phase 1
Dec 2022
→ May 2029
Phase 1Current
NCT06852503
1,017 pts·MG
2022-12→2029-05·Terminated
1,017 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2029-05-063.1y awayInterim· MG
Trial Timeline
2023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2
P1
Termina…
Catalysts
Interim
2029-05-06 · 3.1y away
MG
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06852503 | Phase 1 | MG | Terminated | 1017 | BodyWt |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Terafutibatinib | Pfizer | Phase 1/2 | CD38 | |
| Sotovorutinib | Pfizer | Approved | Aβ | |
| ABB-3060 | AbbVie | Phase 2 | LAG-3 | |
| ABB-3951 | AbbVie | Phase 2/3 | TNFα | |
| GIL-6239 | Gilead Sciences | Phase 2 | TNFα | |
| Tezecilimab | Regeneron | Approved | IL-23 | |
| MRN-8225 | Moderna | Preclinical | TNFα | |
| Sovanaritide | Argenx | Phase 3 | TNFα | |
| INC-2432 | Incyte | Phase 2 | CD47 | |
| Sematapinarof | Legend Biotech | NDA/BLA | VEGF |